Trial
NCT02574910
Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Michigan; Children's Hospital Los Angeles
Condition
Congenital Adrenal Hyperplasia
Intervention
Abiraterone acetate
Why stopped
The study has been affected significantly by the COVID pandemic, drug supply/drug amendment, low recruitment interest, and FDA approval of another drug with the same indication, so this study has not met its primary endpoint data requirements.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-04